- Presentation will highlight Tivic Health’s recent advancements in vagus nerve stimulation -

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that CEO Jennifer Ernst will presenting at the upcoming BioFuture 2024 Conference in New York, October 28-30. Ms. Ernst’s presentation, Tuesday, October 29 at 2:30 p.m. EDT, will focus on the company’s advances in bioelectronic medicine, including its recently released data on a new approach to vagus nerve stimulation.

“This year, BioFuture 2024 has a strong focus on bioelectronic medicine, with industry leaders taking the stage,” highlighted Jennifer Ernst, CEO of Tivic Health. “We are pleased to be included in the event, that leads off with a Fireside Chat with Dr. Kevin Tracey, a pioneer in the field of bioelectronic medicine and CEO & President of The Feinstein Institutes for Medical Research – our clinical partners in development of our vagus nerve stimulation platform. Further reinforcing the importance of this field, Dr Tracey’s presentation will be followed by an industry panel on the promise of neuromodulation for therapeutic care. These are strong indicators of the growing investor and clinical interests in bioelectronic medicine and specifically in vagus nerve stimulation.”

According to BioFuture 2024, these sessions will explore how vagus nerve stimulation “is revolutionizing treatment of conditions such as Rheumatoid arthritis, Crohn’s disease, even cancer, diabetes and mental health conditions.”

Jennifer Ernst will be available for one-on-one meetings with potential investors and partners through the BioFuture Showcase Partnering Platform via this link: https://www.hellopartnering.com/home, or by contacting Tivic Health at: ir@tivichealth.com. A virtual component will follow from November 5-7, offering global attendees access to recorded sessions and additional virtual one-on-one meetings.

About Tivic Health Systems, Inc.

Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is an FDA approved, handheld bioelectronic sinus device available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumption that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

Media Contact: Morgan Luke Morgan.Luke@tivichealth.com

Investor Contact: Hanover International, Inc. ir@tivichealth.com

Tivic Health Systems (NASDAQ:TIVC)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Tivic Health Systems
Tivic Health Systems (NASDAQ:TIVC)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Tivic Health Systems